Literature DB >> 1385585

Age stability of human brain 5-HT terminals studied with [3H]paroxetine binding.

A Andersson1, I Sundman, J Marcusson.   

Abstract

The effect of age on serotonin uptake sites labeled with [3H]paroxetine was studied in two sets of brains. The first set included 28 subjects (19 males and 9 females) between the ages 0 and 100 years. The cortex of cingulate gyrus and the amygdala were studied. No age-related changes in binding capacity (Bmax) or binding affinity (Kd) were noted. In the second set, the frontal cortex and hypothalamus from 22 subjects (18 males and 4 females) between 16 and 75 years were studied. No age-related changes in the binding were observed. The interval between death and freezing of the tissue did not influence the binding. Regarding the [3H]paroxetine binding as an indirect marker for 5-HT terminals, the data suggest a stability of 5-HT terminals with increasing age in the human brain.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1385585     DOI： 10.1159/000213319

Source DB:  PubMed          Journal:  Gerontology        ISSN： 0304-324X            Impact factor:   5.140


  7 in total

1.  High affinity [3H]imipramine and [3H]paroxetine binding sites in suicide brains.

Authors:  P Rosel; B Arranz; J Vallejo; M Oros; J M Menchón; P Alvarez; M A Navarro
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Brain monoaminergic and neuropeptidergic variations in human aging.

Authors:  B Arranz; K Blennow; R Ekman; A Eriksson; J E Månsson; J Marcusson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Is correction for age necessary in neuroimaging studies of the central serotonin transporter?

Authors:  Swen Hesse; Henryk Barthel; Toshiya Murai; Ulrich Müller; Dominic Müller; Anita Seese; Regine Kluge; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-16       Impact factor: 9.236

4.  Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls.

Authors:  Walter Koch; Marcus Unterrainer; Guoming Xiong; Peter Bartenstein; Markus Diemling; Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Morten Ziebell; Jacques Darcourt; Flavio Nobili; Marco Pagani; Swen Hesse; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-08       Impact factor: 9.236

Review 5.  Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.

Authors:  S M Holliday; G L Plosker
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

6.  Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine.

Authors:  L Naylor; B Dean; K Opeskin; G Pavey; C Hill; N Keks; D Copolov
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

7.  The effects of ecstasy (MDMA) on brain serotonin transporters are dependent on age-of-first exposure in recreational users and animals.

Authors:  Anne Klomp; Bjørnar den Hollander; Kora de Bruin; Jan Booij; Liesbeth Reneman
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.